Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Breast 3Other 2Tumor-Agnostic 1Lymphoid 1Endocrine 1

Conditions

Muscle Weakness 1Multiple Endocrine Neoplasia Type 1 1Motor Activity 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Nivolumab 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Testosterone × Endocrine × Clear all
NCT02873559 2024-05-29

PROGRESS

University Hospital, Gentofte, Copenhagen

Phase 2/3 Completed
192 enrolled
Endocrine

Motor Activity, Multiple Endocrine Neoplasia Type 1, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡